Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma

This case of acute renal allograft rejection following treatment with immune checkpoint inhibitor therapy for metastatic melanoma highlights specific concerns regarding use of anti-PD-1 agents such as nivolumab. Given rates of adverse events are generally much lower with anti-PD-1 antibodies compared with anti-CTLA-4 antibodies, there is potential for error in the generalisation of perceived safety.

from Cancer via ola Kala on Inoreader http://ift.tt/1TnWkFY
via IFTTT